SCHEMBL1574699

SCHEMBL1574699

COC(=O)c1cccc(NC(=O)N2CC(N(C(C)C)C(C)C)C2)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.49
LMNA P02545 1/20 0.48
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 2/20 0.47
UBE2M P61081 1/20 0.46
DCUN1D1 Q96GG9 1/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 2/20 0.46
MAPT P10636 2/20 0.46
EPHX2 P34913 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TP53 P04637 1/20 0.45
CASR P41180 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
RHOA P61586 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574467 0.87 RAB9A (0.52) RAB9ALMNAALDH1A1SMN1; SMN2NPC1
SCHEMBL1575708 0.85 CASR (0.53) RAB9ALMNAALDH1A1SMN1; SMN2HSD17B10
SCHEMBL1574383 0.84 L3MBTL1 (0.50) RAB9ALMNAALDH1A1SMN1; SMN2HSD17B10
SCHEMBL1574497 0.83 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2NPC1POLBMAPT
SCHEMBL1573328 0.83 ALDH1A1 (0.59) RAB9ALMNAALDH1A1SMN1; SMN2HSD17B10
SCHEMBL1575244 0.82 ALDH1A1 (0.58) RAB9AALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL1574713 0.82 RAB9A (0.47) RAB9ALMNAALDH1A1SMN1; SMN2HSD17B10
SCHEMBL1574592 0.82 RAB9A (0.53) RAB9ALMNAALDH1A1SMN1; SMN2HSD17B10
SCHEMBL1575148 0.82 RAB9A (0.47) RAB9ALMNAALDH1A1SMN1; SMN2NPC1
SCHEMBL1574702 0.81 GRIN2B (0.52) RAB9AALDH1A1SMN1; SMN2NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB RAB9A 898/4885LMNA 1076/4885ALDH1A1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.